AstraZeneca Pharma India is set to launch Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in November 2025 in India. This follows earlier communications and receipt of necessary marketing permissions. Lokelma is indicated for the treatment of hyperkalaemia in adult patients and marks a significant addition to AstraZeneca’s product portfolio in India.
Lokelma Launch Announcement
AstraZeneca Pharma India Limited has announced the upcoming launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma). The launch is scheduled for November 2025 in India.
Product Indication
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is specifically indicated for the treatment of hyperkalaemia in adult patients. This launch expands treatment options for this condition within the Indian market.
Background and Approvals
This launch follows previous communications and the receipt of Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India for Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma). This regulatory approval facilitated the upcoming market launch.
Source: BSE
